Cosmo Pharmaceuticals NV (XSWX:COPN) EBIT per Share : CHF0.61 (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cosmo Pharmaceuticals NV EBIT per Share?

Cosmo Pharmaceuticals NV's EBIT per Share for the six months ended in Dec. 2023 was CHF0.11. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.61.

During the past 12 months, the average EBIT per Share Growth Rate of Cosmo Pharmaceuticals NV was -75.10% per year. During the past 3 years, the average EBIT per Share Growth Rate was -6.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Cosmo Pharmaceuticals NV's EBIT per Share or its related term are showing as below:

XSWX:COPN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.1 Med: 18.15 Max: 72.9
Current: -6.6

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Cosmo Pharmaceuticals NV was 72.90% per year. The lowest was -45.10% per year. And the median was 18.15% per year.

XSWX:COPN's 3-Year EBIT Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.3 vs XSWX:COPN: -6.60

Cosmo Pharmaceuticals NV's EBIT for the six months ended in Dec. 2023 was CHF1.75 Mil.

Cosmo Pharmaceuticals NV EBIT per Share Historical Data

The historical data trend for Cosmo Pharmaceuticals NV's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cosmo Pharmaceuticals NV EBIT per Share Chart

Cosmo Pharmaceuticals NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.95

0.14

2.03

2.02

0.59

Cosmo Pharmaceuticals NV Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT per Share	Get a 7-Day Free Trial															1.78	0.85	1.21	0.50	0.11

Cosmo Pharmaceuticals NV EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Cosmo Pharmaceuticals NV's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	9.485	/	16.105
=	0.59

Cosmo Pharmaceuticals NV's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	1.745	/	16.064
=	0.11

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF0.61

Cosmo Pharmaceuticals NV (XSWX:COPN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Cosmo Pharmaceuticals NV EBIT per Share Related Terms

Thank you for viewing the detailed overview of Cosmo Pharmaceuticals NV's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cosmo Pharmaceuticals NV (XSWX:COPN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cosmo Pharmaceuticals NV (XSWX:COPN) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

CMOPF:USA COPNz:UK C43:Germany

Address

Sir John Rogerson’s Quay, Riverside II, Dublin, IRL, 2

Website

https://www.cosmopharma.com

Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.

Cosmo Pharmaceuticals NV (XSWX:COPN) Headlines

No Headlines